VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population

Zhang, Y.; Zhang, J. Q.; Liu, Z. H.; Xiong, Chunhui; Ni, Xiuqin; Hui, Rutai; He, Jing; Pu, Jiayuan

doi:10.1111/j.1399-0004.2009.01196.x

Cited by 8 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in Caucasian group the expression of gene variant was not significantly different in PH patients compared with the controls. [195,196]. In a study from Austria, patients with idiopathic PAH exhibited low VIP levels and poor response to inhaled NO.…”

Section: Vasoactive Intestinal Peptide (Vip)mentioning

confidence: 97%

Pulmonary Hypertension: Current Therapy and Future Prospects

Mathew¹

2011

CHAMC

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a sequel of a variety of cardiovascular and systemic diseases. Heterozygous mutation of BMPRII, a member of the TGFβ superfamily is the commonest genetic defect so far identified in PH. Recent advances have contributed a great deal to the understanding of the disease; however, the actual mechanism/s is not yet clear. Endothelial damage is the key underlying feature of PH. The main effects are loss of vascular relaxation response, increased cell proliferation and impaired apoptosis, matrix deposition, obstruction in the small pulmonary arteries, right ventricular hypertrophy; and eventually leading to right heart failure and death. The diagnosis of PH is often made late because of the insidious onset of symptoms, therefore the treatment poses a daunting challenge. Furthermore, depending on the underlying pathology, not all patients respond equally to same therapeutic agents. Current therapy includes a group of drugs mainly involved in improving vascular relaxation (cAMP and cGMP mechanisms) and endothelin receptor blockers alone or in combination. Newer drugs such as guanylate cyclase activators, PDGF blocker, RhoA/Rho kinase blockers have shown encouraging results in animal studies and in a few clinical cases of PH. Other drugs and signaling pathways such as nitrites, PPARγ, ACE2, ghrelin etc. are under investigation. Studies with gene therapy are being actively pursued. This review summarizes the available therapy and the future prospects.

show abstract

Section: Vasoactive Intestinal Peptide (Vip)mentioning

confidence: 97%

Pulmonary Hypertension: Current Therapy and Future Prospects

Mathew¹

2011

CHAMC

View full text Add to dashboard Cite

show abstract

“…Knockout mice lacking the VIP gene or humans presenting polymorphism of sequences encoding VIP are affected by PAH, [17][18][19] as are patients with an underexpression of constitutive secretion of NO. 20 Thus, a diminution of VIP was expected; however, the measurement showed an unexpected and interesting increase.…”

Section: Figmentioning

confidence: 99%

Role of Vasoactive Intestinal Peptide in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension

Lacedonia

ValerioGiuseppe

Pia

et al. 2014

Rejuvenation Research

View full text Add to dashboard Cite

show abstract

“…The 3' untranslated region in exon 7 is mutated (g.8129T>C) leading to reduced VIP serum levels and higher pulmonary artery pressure (Zhang et al, 2009). …”

Section: Notementioning

confidence: 99%

VIP (vasoactive intestinal peptide)

Moody¹

2014

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

Review on VIP, with data on DNA/RNA, on the protein encoded and where the gene is implicated. IdentityOther names: PHM27 HGNC (Hugo): VIP Location: 6q25.2 Local order: The VIP gene has 7 exons. Note: VIP is a secreted protein which binds to membrane G-protein coupled receptors (GPCR) increasing intracellular cAMP signaling. DNA/RNA NoteThe human VIP gene encodes 7 exons and is localized to chromosome 6q25.2 (Fahrenkrug, 2010). DescriptionThe VIP gene spans 8837 bp. TranscriptionThe gene transcript has 1601 bp. ProteinDescription Said and Mutt (1970) sequenced an acid extractable peptide from the porcine duodenum which decreased systemic arterial pressure and increased heart rate, stroke volume, mesenteric and femoral blood flow in the dog. The 27 amino acid peptide was named vasoactive intestinal peptide (VIP). VIP is metabolized (Bodner et al., 1985) from a 170 amino acid precursor protein (preproVIP).

show abstract

VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population

Cited by 8 publications

References 23 publications

Pulmonary Hypertension: Current Therapy and Future Prospects

Pulmonary Hypertension: Current Therapy and Future Prospects

Role of Vasoactive Intestinal Peptide in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension

VIP (vasoactive intestinal peptide)

Contact Info

Product

Resources

About